These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36404761)

  • 1. Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes.
    Tokita J; Vega A; Sinfield C; Naik N; Rathi S; Martin S; Wang S; Amoruso L; Zabetian A; Coca SG; Nadkarni GN; Fleming F; Donovan MJ; Fields R
    J Prim Care Community Health; 2022; 13():21501319221138196. PubMed ID: 36404761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease.
    Tokita J; Lam D; Vega A; Wang S; Amoruso L; Muller T; Naik N; Rathi S; Martin S; Zabetian A; Liu C; Sinfield C; McNicholas T; Fleming F; Coca SG; Nadkarni GN; Tun R; Kattan M; Donovan MJ; Rahim AK
    J Prim Care Community Health; 2024; 15():21501319231223437. PubMed ID: 38185870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
    Lam D; Nadkarni GN; Mosoyan G; Neal B; Mahaffey KW; Rosenthal N; Hansen MK; Heerspink HJL; Fleming F; Coca SG
    Am J Nephrol; 2022; 53(1):21-31. PubMed ID: 35016188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A kidney diagnostic's impact on physician decision-making in diabetic kidney disease.
    Datar M; Ramakrishnan S; Chong J; Montgomery E; Goss TF; Coca SG; Vassalotti JA
    Am J Manag Care; 2022 Dec; 28(12):654-661. PubMed ID: 36525658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.
    Chan L; Nadkarni GN; Fleming F; McCullough JR; Connolly P; Mosoyan G; El Salem F; Kattan MW; Vassalotti JA; Murphy B; Donovan MJ; Coca SG; Damrauer SM
    Diabetologia; 2021 Jul; 64(7):1504-1515. PubMed ID: 33797560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Payer budget impact of an artificial intelligence
    Datar M; Burchenal W; Donovan MJ; Coca SG; Wang E; Goss TF
    J Med Econ; 2021; 24(1):972-982. PubMed ID: 34304681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.
    Nadkarni GN; Stapleton S; Takale D; Edwards K; Moran K; Mosoyan G; Hansen MK; Donovan MJ; Heerspink HJL; Fleming F; Coca SG
    Diabetes Obes Metab; 2023 Dec; 25(12):3779-3787. PubMed ID: 37722962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A
    Nadkarni GN; Takale D; Neal B; Mahaffey KW; Yavin Y; Hansen MK; Fleming F; Heerspink HJL; Coca SG
    Kidney360; 2022 Sep; 3(9):1599-1602. PubMed ID: 36245651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes.
    Chauhan K; Nadkarni GN; Fleming F; McCullough J; He CJ; Quackenbush J; Murphy B; Donovan MJ; Coca SG; Bonventre JV
    Kidney360; 2020 Aug; 1(8):731-739. PubMed ID: 35372952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.
    Kitaoka K; Yano Y; Nagasu H; Kanegae H; Chishima N; Akiyama H; Tamura K; Kashihara N
    BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38816204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
    Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.
    Helou N; Dwyer A; Shaha M; Zanchi A
    JBI Database System Rev Implement Rep; 2016 Jul; 14(7):169-207. PubMed ID: 27532796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
    Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
    Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.